Provided by Tiger Trade Technology Pte. Ltd.

Warrior Met Coal LLC

91.80
-0.9200-0.99%
Post-market: 91.800.00000.00%17:27 EDT
Volume:612.18K
Turnover:56.42M
Market Cap:4.83B
PE:22.07
High:95.91
Open:94.14
Low:91.47
Close:92.72
52wk High:111.42
52wk Low:60.70
Shares:52.57M
Float Shares:51.78M
Volume Ratio:0.84
T/O Rate:1.18%
Dividend:0.32
Dividend Rate:0.35%
EPS(TTM):4.16
EPS(LYR):1.08
ROE:10.04%
ROA:5.17%
PB:2.11
PE(LYR):85.00

Loading ...

NYSE Order Imbalance 56938.0 Shares on Sell Side

THOMSON REUTERS
·
Yesterday

RBC Raises Price Target on Warrior Met Coal to $110 From $90, Keeps Sector Perform Rating

MT Newswires Live
·
Sep 16

WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC

GlobeNewswire
·
Sep 14

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

GlobeNewswire
·
Sep 09

Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Dow Jones
·
Sep 08

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

GlobeNewswire
·
Sep 02

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

GlobeNewswire
·
Sep 02

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewswire
·
Sep 01

Tokio Marine HCC International Acquires UK-Based Direct Commercial

MT Newswires Live
·
Aug 31

Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

Dow Jones
·
Aug 28

IMMUNEONCO-B Advances Phase II Trial for First-Line Advanced Liver Cancer Therapy With Initial Patient Dosing Completed

Stock News
·
Aug 27

Warrior Met Coal CEO Walter J. Scheller Sells 50,000 Shares for $5.5 Million

Reuters
·
Aug 26

Warrior Met Coal Inc : Jefferies Raises Target Price to $125 from $110

THOMSON REUTERS
·
Aug 26

Press Release: Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors

Dow Jones
·
Aug 25

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

GlobeNewswire
·
Aug 25

Press Release: Antengene Announces 2026 Interim Results: Achieves First

Dow Jones
·
Aug 24

Warrior Met Coal Director Stephen D. Williams Sells 4,800 Common Shares Worth $500,304

Reuters
·
Aug 22

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

GlobeNewswire
·
Aug 20

Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer

GlobeNewswire
·
Aug 17

Tvardi: Strategic Pivot to Ulcerative Colitis and Upcoming HCC Readouts Support Unchanged $9 Price Target and Buy Rating

TIPRANKS
·
Aug 15